<DOC>
	<DOCNO>NCT01140009</DOCNO>
	<brief_summary>The seasonal influenza vaccination program 2010-2011 first follow H1N1 pandemic 2009 . Many Canadians either H1N1 infection adjuvanted H1N1 vaccine . Both H1N1 infection adjuvanted vaccine produce strong immune response could last time . The seasonal influenza vaccine fall `` normal '' product , without adjuvant . It contain 3 strain kill , split-apart virus might circulate winter , include H1N1 pandemic strain . It theoretically possible give H1N1-containing seasonal vaccine people still immunity H1N1 virus could result frequent side-effects . However , good evidence pre-existing immunity strain vaccine increase side-effects . In short , could nothing ordinary fall would prudent check public flu vaccination program begin .</brief_summary>
	<brief_title>Safety Protectiveness Seasonal Influenza Vaccine 2010-2011</brief_title>
	<detailed_description>This study ass safety seasonal influenza vaccination people adjuvanted H1N1 vaccine last year . It also measure residual immunity H1N1 virus immune responses seasonal vaccine . It carry new vaccine release general use accurate picture vaccine safety response Canadians . A total 320 adult ( 64 site ) 20 59 year old , ask participate study . A research nurse conduct telephone screen potential participant determine eligible study . Volunteers must adjuvanted H1N1 vaccine January 31 , 2010 . The study involve 2 vaccination visit 10 day part . At one visit seasonal vaccine give placebo vaccine give . Which vaccine give first determine random chance , detail release study end . After vaccination , contact 1 7 day later description symptom experience . A blood sample request first last visit ( visit 3 ) measure immune response seasonal vaccine . The study take 21-38 day complete , depend upon vaccination sequence availability . Total time require take part 2.5 hour . The 3 study visit occur clinic Vancouver , Calgary , Ottawa , Montreal Quebec City . Each subject ask keep daily note change injection site ( pain , redness , swell ) general symptom ( headache , tiredness , body ache ) , include oral temperature , 7 day vaccination . Major health change assess 21 day post 'vaccination ' A special Safety Board review result first vaccination advise whether reasonable continue study .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Written inform consent Can comply requirement protocol Age 2059 year Visit 1 Receipt one dose Arepanrix ( adjuvanted H1N12009 vaccine , GSK ) 2009 document write record attest confident personal recollection ( window vaccination 1 October 2009 January 31 , 2010 ) . Systemic hypersensitivity hen ' egg Fluviral S/F vaccine component thimerosal History lifethreatening reaction influenza vaccine Receipt nonstudy TIV 20102011 season Receipt live vaccine within 4 week inactivate vaccine within one week study entry plan administration nonstudy vaccine study period Thrombocytopenia bleed disorder contraindicates IM injection blood collection Pregnancy , stage gestation Receipt blood bloodderived product within 3 month prior Visit 1 Chronic illness stage could interfere trial participation ( stable health condition acceptable , diabetes , lung disease , heart condition etc ) History GuillainBarre syndrome Immune compromise result illness immunosuppressive medication Participation research study involve nonapproved drug medical device Any condition may interfere ability comply trial procedure , include abuse alcohol , drug addiction impose confinement Current febrile illness oral temperature ≥ 38.0 °C</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Vaccine</keyword>
	<keyword>Seasonal Influenza vaccine</keyword>
	<keyword>Influenza vaccine</keyword>
	<keyword>Vaccine safety</keyword>
	<keyword>Vaccine immunogenicity</keyword>
	<keyword>Fluviral 2010/11</keyword>
</DOC>